124 related articles for article (PubMed ID: 9315993)
1. Two rapid-dose titrations of sertindole in patients with schizophrenia.
Sramek JJ; Mack RJ; Awni W; Hourani J; Jhee SS; Barto S; Cutler NR
J Clin Psychopharmacol; 1997 Oct; 17(5):419-22. PubMed ID: 9315993
[TBL] [Abstract][Full Text] [Related]
2. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB
Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505
[TBL] [Abstract][Full Text] [Related]
3. Dose-response relationship of sertindole and haloperidol using the pharmacopsychometric triangle.
Bech P; Tanghøj P; Andreasson K; Overø KF
Acta Psychiatr Scand; 2011 Feb; 123(2):154-61. PubMed ID: 20560900
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia.
Azorin JM; Strub N; Loft H
Int Clin Psychopharmacol; 2006 Jan; 21(1):49-56. PubMed ID: 16317317
[TBL] [Abstract][Full Text] [Related]
5. Augmenting clozapine with sertindole: a double-blind, randomized, placebo-controlled study.
Nielsen J; Emborg C; Gydesen S; Dybbro J; Aagaard J; Haderup K; Glyngdal P; Fabricius S; Thode D; Lublin H; Andersen T; Damkier P; Taylor D
J Clin Psychopharmacol; 2012 Apr; 32(2):173-8. PubMed ID: 22367659
[TBL] [Abstract][Full Text] [Related]
6. Sertindole: dilemmas for its use in clinical practice.
Pae CU
Expert Opin Drug Saf; 2013 May; 12(3):321-6. PubMed ID: 23432404
[TBL] [Abstract][Full Text] [Related]
7. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia.
van Kammen DP; McEvoy JP; Targum SD; Kardatzke D; Sebree TB
Psychopharmacology (Berl); 1996 Mar; 124(1-2):168-75. PubMed ID: 8935813
[TBL] [Abstract][Full Text] [Related]
8. A review of the efficacy, tolerability and safety of sertindole in clinical trials.
Perquin L; Steinert T
CNS Drugs; 2004; 18 Suppl 2():19-30; discussion 41-3. PubMed ID: 15461313
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance.
Pezawas L; Quiner S; Moertl D; Tauscher J; Barnas C; Küfferle B; Wolf R; Kasper S
Int Clin Psychopharmacol; 2000 Jul; 15(4):207-14. PubMed ID: 10954060
[TBL] [Abstract][Full Text] [Related]
10. Sertindole in the long-term treatment of schizophrenia.
Hale AS; Azorin JM; Lemming OM; Mæhlum E
Int Clin Psychopharmacol; 2012 Jul; 27(4):231-7. PubMed ID: 22609816
[TBL] [Abstract][Full Text] [Related]
11. Status epilepticus associated with sertindole.
Sinn DI; Chu K; Jung KH; Park KI; Nam H; Lee SK
Eur J Neurol; 2007 Aug; 14(8):e12-3. PubMed ID: 17661989
[No Abstract] [Full Text] [Related]
12. Modeling of sertindole pharmacokinetic disposition in healthy volunteers in short term dose-escalation studies.
Wong SL; Granneman GR
J Pharm Sci; 1998 Dec; 87(12):1629-31. PubMed ID: 10189278
[TBL] [Abstract][Full Text] [Related]
13. In vivo effects on striatal dopamine D2 receptor binding by the novel atypical antipsychotic drug sertindole--a 123I IBZM single photon emission tomography (SPET) study.
Pilowsky LS; O'Connell P; Davies N; Busatto GF; Costa DC; Murray RM; Ell PJ; Kerwin RW
Psychopharmacology (Berl); 1997 Mar; 130(2):152-8. PubMed ID: 9106913
[TBL] [Abstract][Full Text] [Related]
14. Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety.
Tamminga CA; Mack RJ; Granneman GR; Silber CJ; Kashkin KB
Int Clin Psychopharmacol; 1997 Feb; 12 Suppl 1():S29-35. PubMed ID: 9179641
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of 12 weeks of treatment with sertindole or olanzapine in patients with chronic schizophrenia who did not respond successfully to their previous treatments: a randomized, double-blind, parallel-group, flexible-dose study.
Kwon JS; Mittoux A; Hwang JY; Ong A; Cai ZJ; Su TP
Int Clin Psychopharmacol; 2012 Nov; 27(6):326-35. PubMed ID: 22850268
[TBL] [Abstract][Full Text] [Related]
16. Emerging treatments in the management of schizophrenia - focus on sertindole.
Muscatello MR; Bruno A; Pandolfo G; Micò U; Settineri S; Zoccali R
Drug Des Devel Ther; 2010 Sep; 4():187-201. PubMed ID: 20856845
[TBL] [Abstract][Full Text] [Related]
17. Effect of sertindole on QTc interval in patients with schizophrenia.
Atmaca M; Yavuzkir M; Mermi O; Topuz M; Kanmaz E; Tezcan E
Neurosci Lett; 2008 Sep; 442(1):1-3. PubMed ID: 18639380
[TBL] [Abstract][Full Text] [Related]
18. Sertindole: new drug. Another "atypical" neuroleptic; QT prolongation.
Prescrire Int; 2007 Apr; 16(88):59-62. PubMed ID: 17458045
[TBL] [Abstract][Full Text] [Related]
19. Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol.
Gallhofer B; Jaanson P; Mittoux A; Tanghøj P; Lis S; Krieger S
Pharmacopsychiatry; 2007 Nov; 40(6):275-86. PubMed ID: 18030652
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of patients on sertindole treatment after failure of other antipsychotics: a retrospective analysis.
Azorin JM; Murteira S; Hansen K; Toumi M
BMC Psychiatry; 2008 Mar; 8():16. PubMed ID: 18366634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
